No results for ‘’
Glenmark Pharmaceuticals Ltd
₹2233.90
(1.99%)
Tue, 04 Aug 2026, 02:01 am
Health Technology
Pharmaceuticals: Major
24.5KGlenmark Pharmaceuticals Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 49.02 | 26.38 | 19.66 | 21.04 | 21.44 | 16.92 | 18.09 | 20.39 | 28.30 | 44.86 | 31.77 | 26.43 | 19.22 | 19.69 | 7.49 | 13.51 | 13.25 | 44.14 | 0 | 41.51 |
| Price to book ratio | 10 | 10.67 | 8.04 | 2.47 | 3.05 | 3.76 | 3.47 | 4.53 | 5.14 | 7.11 | 5.25 | 4.90 | 2.66 | 3.25 | 0.96 | 1.86 | 1.37 | 1.38 | 3.44 | 4.91 |
| Price to sales ratio | 6.27 | 6.86 | 6.43 | 1.97 | 2.86 | 2.60 | 2.07 | 2.50 | 2.59 | 3.27 | 2.95 | 2.67 | 1.64 | 1.87 | 0.55 | 1.21 | 1.01 | 1.13 | 2.29 | 3.26 |
| Price to cash flow ratio | 0 | 147.77 | 40.23 | 0 | 37.10 | 9.73 | 12.85 | 24.70 | 23.04 | 69.95 | 128.71 | 49.13 | 10.30 | 17.22 | 5.30 | 15.59 | 14.38 | 38.94 | 0 | 0 |
| Enterprise value | 4885Cr | 8988Cr | 13259Cr | 6049Cr | 8728Cr | 9613Cr | 10274Cr | 14712Cr | 17807Cr | 24350Cr | 25432Cr | 27876Cr | 18281Cr | 21658Cr | 9880Cr | 16945Cr | 15374Cr | 16925Cr | 26584Cr | 44222Cr |
| Enterprise value to EBITDA ratio | 36.21 | 21.18 | 16.68 | 13.51 | 13.44 | 16.23 | 14.38 | 14.57 | 13.73 | 21.28 | 17.75 | 13.69 | 11.30 | 14.66 | 6.05 | 8.04 | 6.49 | 10.13 | 21.58 | 18.56 |
| Debt to equity ratio | 1.87 | 1.36 | 0.65 | 1.31 | 0.79 | 1.04 | 0.93 | 1 | 1.10 | 1.27 | 0.93 | 0.96 | 0.83 | 0.79 | 0.85 | 0.71 | 0.44 | 0.49 | 0.16 | 0.28 |
| Return on equity % | 24.37 | 57.45 | 57.36 | 12.30 | 16.41 | 20.64 | 20.74 | 23.81 | 18.87 | 15.89 | 19.31 | 19.89 | 14.71 | 16.53 | 12.86 | 14.77 | 11.66 | -1.83 | -21.93 | 12.54 |
Glenmark Pharmaceuticals Ltd Enterprise Value
The Glenmark Pharmaceuticals Ltd Enterprise Value is a key financial metric used by investors to evaluate Glenmark Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Glenmark Pharmaceuticals Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Glenmark Pharmaceuticals Ltd (NSE: GLENMARK, BSE: 532296) is currently trading at ₹2233.90, with a market capitalization of ₹63023.91Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Glenmark Pharmaceuticals Ltd Enterprise Value is essential for fundamental analysis.
Glenmark Pharmaceuticals Ltd Enterprise Value Current Value
The current Glenmark Pharmaceuticals Ltd Enterprise Value stands at 44222Cr.
The latest Glenmark Pharmaceuticals Ltd Enterprise Value has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Glenmark Pharmaceuticals Ltd Enterprise Value Historical Trend
The Glenmark Pharmaceuticals Ltd Enterprise Value has shown the following historical trend:
- 2024: 44222Cr
- 2023: 26584Cr
- 2022: 16925Cr
- 2021: 15374Cr
- 2020: 16945Cr
The recent rise in Glenmark Pharmaceuticals Ltd Enterprise Value suggests strengthening valuation trends and improving market sentiment.
What Glenmark Pharmaceuticals Ltd Enterprise Value Indicates for Investors
The Glenmark Pharmaceuticals Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd Enterprise Value Analysis Summary
The Glenmark Pharmaceuticals Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Glenmark Pharmaceuticals Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Glenmark Pharmaceuticals Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.